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ARTICLE
Genome-wide association study of smoking
trajectory and meta-analysis of smoking status
in 842,000 individuals
Ke Xu1,2,7, Boyang Li 2,3,7, Kathleen A. McGinnis2, Rachel Vickers-Smith4, Cecilia Dao2,3, Ning Sun3,
Rachel L. Kember5,6, Hang Zhou 1,2, William C. Becker1,2, Joel Gelernter 1,2, Henry R. Kranzler 5,6,
Hongyu Zhao 1,3, Amy C. Justice 1,2✉ & VA Million Veteran Program*
Here we report a large genome-wide association study (GWAS) for longitudinal smoking
phenotypes in 286,118 individuals from the Million Veteran Program (MVP) where
we identified 18 loci for smoking trajectory of current versus never in European Americans,
one locus in African Americans, and one in Hispanic Americans. Functional annotations
prioritized several dozen genes where significant loci co-localized with either expression
quantitative trait loci or chromatin interactions. The smoking trajectories were genetically
correlated with 209 complex traits, for 33 of which smoking was either a causal or a
consequential factor. We also performed European-ancestry meta-analyses for smoking
status in the MVP and GWAS & Sequencing Consortium of Alcohol and Nicotine use
(GSCAN) (Ntotal= 842,717) and identified 99 loci for smoking initiation and 13 loci for
smoking cessation. Overall, this large GWAS of longitudinal smoking phenotype in multiple
populations, combined with a meta-GWAS for smoking status, adds new insights into the
genetic vulnerability for smoking behavior.
https://doi.org/10.1038/s41467-020-18489-3 OPEN
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C igarette smoking has an estimated heritability of 40–70%
1,2,
and is a leading cause of morbidity and mortality worldwide.
In the past two decades, over 25 genome-wide association
studies (GWAS) of smoking and smoking-related phenotypes
have been reported3–9. Among several hundred reported loci, the
established loci are predominantly in a few genomic regions, such as
15q25 (CHRNA5-A3-B4) and 8p11 (CHRNB3-CHRNA6)3,4,10,11.
Large meta-GWASs have been reported, including a study from the
UK Biobank (UKBB) and the Tobacco and Genetics Consortium
(TAG) with a total of 518,633 individuals that identified 223 loci for
ever versus (vs.) never smokers10. These genetic variants accounted
for 10.9% of the phenotypic variation for this single trait10.
The largest meta-GWAS to date by the GWAS & Sequencing
Consortium of Alcohol and Nicotine use (GSCAN) included up
to a total of 1.2 million individuals (depending on traits) from
26 cohorts and identified 406 loci associated with multiple stages
of cigarette use (initiation, cessation, and heaviness)5. In that
study, genetic heritability was 4–8% for smoking phenotypes5.
A meta-analysis GWAS of up to 61 studies identified 40 new rare
or low-frequency variants associated with smoking behavior6.
However, none of the large GWAS studies identified genetic var-
iants for smoking trajectories.
Smoking is a complex trait typically ascertained by self-reported
responses to questionnaires. Phenotypes previously used for GWAS
include self-reported ever vs. never smoked3,12–14, number of
cigarettes smoked per day (CPD)3,9,14, age of initiation, smoking
cessation, and nicotine dependence defined by the Fagerström Test
for Nicotine Dependence (FTND)7,15. However, single measures of
self-reported health behaviors, especially those that are stigmatized
like smoking, are subject to social desirability bias and substantially
underestimate smoking16, and they often measure state rather than
trait. Biomarkers for nicotine exposure offer less biased metrics and
have demonstrated strong associations with genetic markers17,18.
For example, the nicotine metabolite ratio, which can be estimated
in blood, provided an estimated heritability as high as 0.81 and was
linked to 19q1319,20. However, the feasibility of using biomarkers
for large-scale gene discovery is limited. In contrast, electronic
medical records (EMRs) provide an opportunity to obtain large-
scale longitudinal data that can be linked to genetic data. The large
scope of EMR-derived data increases power, overcoming some of
the limitations of state phenotypic measurement. Few studies have
applied a longitudinal smoking phenotype for gene discovery21.
We leverage the EMR-derived longitudinal data to perform
the largest longitudinal smoking GWAS in a multi-ethnic
cohort and identify 16 genetic loci associated with smoking
trajectory contrasts for European American (EA), one locus for
African American (AA), and one locus for Hispanic American
(HA) individuals from the Million Veteran Program (MVP,
N= 286,118). We also meta-analyze smoking status GWASs
from EAs in the MVP and European subjects in GSCAN
(excluding data from 23andMe which summary statistics are not
released for public), yielding a total sample of 842,717 indivi-
duals and leading to the identification of 99 genetic loci asso-
ciated with smoking initiation and 13 loci associated with
smoking cessation. We further characterize the genetic risk for
smoking trajectory by estimating SNP-based heritability, prior-
itizing causal genes and biological pathway interpretation,
determining genetic correlation of smoking trajectory with
psychiatric and nonpsychiatric traits, and exploring the causality
of smoking trajectory with other genetically correlated traits.
The phenotypic characterization of the studied populations is
presented in Table 1 and analytical approach is presented in
Fig. 1. Overall, we identify multiple genetic loci associated with
smoking trajectory contrasts in diverse populations. Our find-
ings highlight the significance of incorporating longitudinal data
in the EMR-derived phenotypes in improving the identification
and biological interpretation of genetic associations character-
izing smoking behaviors for diverse populations.
Results
GWAS for EMR-based smoking trajectories in the MVP. Using
a previously validated approach22 and data from over 2.2 million
clinical encounters (per person mean= 10.5, median= 8) where
smoking status was recorded in the EMR for a total of 286,118
veterans (209,915 EAs, 54,867 AAs, and 21,336 HAs), we iden-
tified three distinct longitudinal trajectory groups for smoking in
each population group. The trajectory groups were defined using
the highest assignment probabilities and were identified as indi-
viduals who mostly never smoked, those with mixed smoking and
nonsmoking and those who, over time, reported mostly current
smoking. As a binary comparison phenotype, we also defined
smoking status as smoking initiation (ever vs. never) and smok-
ing cessation (current vs. past) using a classification method
based on the modal value, i.e., the most common value of all data
available in the same samples. Although the two phenotypes were
highly correlated, by comparing their performance we evaluated
their relative utility for detecting genetic variants contributing to
smoking behavior.
We first conducted a GWAS for smoking trajectories separately
in EA, AA, and HA populations in the MVP, then conducted a
trans-ethnic meta-GWAS for smoking trajectories. We used a
multinomial regression model to analyze the unordered multi-
nomial smoking trajectory groups and adjusted for age, sex, and
ten principal components (PCs) as covariates. The pairwise
smoking trajectory contrasts are current vs. never (contrast I),
which corresponds to smoking initiation, and current vs. mixed
(contrast II), which corresponds to smoking cessation. The two
trajectory contrasts were modeled simultaneously, resulting in
smaller standard error estimates of genetic effects and thus
greater statistical power. The overall fit of the model was
evaluated using the likelihood ratio test.
In the EA samples, we identified 16 independent genome-wide
significant (GWS) loci (pairwise r2 < 0.1) from the likelihood ratio
test on the multinomial smoking trajectories (p < 5 × 10−8)
(Supplementary Table 1) from the overall trajectory model. Seven
of the 16 loci replicated previously reported associations with
smoking or related phenotypes10,11,23,24. The most significant single
nucleotide polymorphism (SNP) was rs7515828 (likelihood ratio
test p= 6.29 × 10−16) near LNC01360 on chromosome 1, which
was recently reported to be significantly associated with smoking in
a large GWAS from the UKBB and TAG10. Analysis for trajectory
contrast I (current vs. never) showed minimal inflation (before
correction λLDSC= 1.0281, se= 0.0096; after LDSC correction
λLDSC= 0.9997, se= 0.0094; and after genomic control correction
λLDSC= 0.8247, se= 0.0078). We identified 18 significant loci for
trajectories of current vs. never with odds ratios (ORs) in the range
of 0.90–1.09 (Table 2 and Supplementary Data 1) (Fig. 2 and
Supplementary Fig. 1). The analysis for contrast II identified five
significant loci for current vs. mixed with ORs ranged from 0.92 to
1.08 (before correction λLDSC= 1.0236, se= 0.0091; after LDSC
correction λLDSC= 1.0000, se= 0.0089; and after genomic control
correction λLDSC= 0.8868, se= 0.0081). Three genes–CHRNA2,
DBH, and DRD2–were GWS in both contrast analyses (Fig. 2).
Based on these findings, we believe that there is an association of
DRD2 with smoking trajectory, although previous findings on this
relationship have been controversial23,25–28. These loci coincide
with the most recent findings from large meta-GWAS5,6.
In the AA samples, we identified one locus for trajectory
contrast I (current vs. never) with the lead SNP rs4478781 near to
LINC01346 (OR= 1.106, Wald test p= 1.06 × 10−8) (Table 2 and
Supplementary Data 1) (Supplementary Fig. 2.1). A previous
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study reported that DNA hydroxymethylation of LINC01346 was
associated with a quantitative measure of neuritic plaque in
Alzheimer disease in human postmortem brain29, suggesting a
potential functional impact of this gene on brain pathology. No
GWS variant was found for trajectory contrast II (current vs.
mixed) in AAs.
In the HA samples, we identified one variant, rs1334346 near
to Regulating Synaptic Membrane Exocytosis 1 (RIMS1) that was
significantly associated with smoking trajectory contrast I
(OR= 0.831, Wald test p= 8.22 × 10−9) (Table 2 and Supple-
mentary Data 1) (Supplementary Fig. 2.2). The protein encoded
by RIMS1 plays a role in the regulation of voltage-gated calcium
channels during neurotransmitter release, and the variants in this
gene were associated with autism30 and schizophrenia31. The
analysis of contrast II (current vs. mixed) for smoking trajectory
revealed no significant variant in HAs.
The trans-ethnic meta-GWAS combining EAs, AAs, and HAs
in the MVP identified 14 GWS loci for contrast I (current vs.
never) and 4 GWS loci for contrast II (current vs. mixed)
(Supplementary Data 2) (Supplementary Fig. 3). The significant
loci largely overlapped with the significant loci of the smoking
trajectory analysis in EAs. For contrast I (current vs. never), 9 of
14 loci overlapped with the significant loci in EAs, and 5 loci were
revealed only by smoking trajectory meta-analysis. For contrast II
(current vs. mixed), the four loci identified by the trans-ethnic
meta-GWAS were identical with the significant loci in EAs. Given
that the sample sizes for AA and HA were relatively limited,
subsequent analyses of smoking status and all downstream
analyses focused on European-ancestry individuals.
GWAS for smoking status. We first identified loci for smoking
status in the EAs from the MVP sample using the phenotypes
of smoking initiation (ever vs. never) and smoking cessation
(current vs. past). Using a logistic regression model, a GWAS for
smoking status showed very little inflation (λLDSC= 1.01 for
initiation and λLDSC= 1.06 for cessation). Twelve loci were GWS
for smoking initiation (Supplementary Data 1) (Supplementary
Fig. 4), including three that were not seen in either the UKBB or
GSCAN studies: GRIK4, SPATS2, and FMNL3. The GWAS for
smoking cessation identified eight GWS loci (Supplementary
Data 1) (Supplementary Fig. 4). Two of eight loci, rs34735365
near to NR5A2 and rs77648866 near to NICN1, were associated
only with smoking cessation and not with smoking initiation.
Of note, previous studies have shown significant associations in
EAs of 15q25 (CHRNA5-A3-B4) and 8p11 (CHRNB3-CHRNA6)
with CPD or FTND32,33. To validate these findings in the MVP
sample, we conducted two GWASs for current CPD (N= 17,014)
and past (N= 77,515) CPD phenotypes in EAs using MVP survey
data, which yielded three GWS for each (Supplementary Table 2).
The most significant signal for current CPD was a well-established
SNP, rs12914385, located in an intron of CHRNA3 on 15q25
(β= 0.014; Wald test p= 4.30 × 10−10). Another significant SNP,
rs3025386, was near DBH (β=−0.017; Wald test p= 1.25 × 10−8),
a gene previously associated with smoking cessation3,24,34.
Table 1 Phenotype distribution of smoking trajectories and demographic characteristics in the Million Veteran Program
(N= 286,118).
Population Mostly current Mixed Mostly never Total Age: mean (SD) Male (%)
EA 40,456 (19%) 110,403 (53%) 59,056 (28%) 209,915 63.8 (13.1) 93.0
AA 13,511 (25%) 23,605 (43%) 17,751 (32%) 54,867 57.7 (11.9) 87.4
HA 2920 (14%) 11,221 (52%) 7195 (34%) 21,336 55.6 (15.1) 92.0
EA European American, AA African American, HA Hispanic American, SD standard deviation.
Smoking trajectory Smoking status
GSCAN
MVP
Contrast I
(current vs. never)
Contrast II
(current vs. mixed)
Smoking initiation
(current + past vs. never)
Smoking cessation
(current vs. past)
Smoking cessation
(exclude 23andMe)
Smoking initiation
Ancestry-specific GWAS
SNP-based h2
Heritability enrichments
Gene prioritization
Pathway enrichments
Genetic correlations
Mendelian randomization
EA AA HA
Trans-ethnic meta
meta EA
Fig. 1 An overview of analyses performed on the smoking trajectory and status phenotypes. MVP the Million Veteran Program; GSCAN the GWAS &
Sequencing Consortium of Alcohol and Nicotine use; EA European American; AA African American; HA Hispanic American; GWAS genome-wide
association study; h2 heritability.
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Table 2 Genome-wide significant associations for smoking trajectories in the Million Veteran Program (N= 286,118).
Smoking trajectory POP CHR:POS SNP EA NEA OR Z P
Contrast I (current vs. never) EA 1: 28717871 rs61783804 T C 0.94 −6.12 9E− 10
1: 28717871 rs76509406 T C 0.90 −5.65 2E− 08
1: 73848331 rs7515828 C T 0.93 −8.24 2E− 16
2: 45159091 rs1004787 A G 1.07 6.88 6E− 12
2: 104496366 rs12477780 T A 1.06 5.64 2E− 08
2: 146118069 rs1474011 A G 0.94 −6.75 1E− 11
4: 152634121 rs28608075 C T 0.92 −5.70 1E− 08
6: 26391395 rs2237235 A G 1.07 5.66 1E− 08
6: 27021173 rs72838268 A G 1.07 5.47 5E− 08
7: 117593308 rs6969783 T A 0.94 −6.65 3E− 11
8: 27336767 rs2565060 A T 1.09 7.13 1E− 12
9: 136471660 rs112270518 G A 0.92 −5.90 4E− 09
11: 112826867 rs2212450 T C 0.95 −6.08 1E− 09
11: 113407114 rs3133388 G A 1.07 6.95 4E− 12
14: 33797853 rs11850899 C T 0.94 −5.74 9E− 09
15: 47844059 rs28505872 C T 0.95 −5.78 7E− 09
16: 69556715 rs889398 C T 1.05 5.64 2E− 08
16: 69953508 rs4985459 A G 1.06 5.77 8E− 09
AA 1: 4086827 rs4478781 C T 1.11 5.72 1E− 08
HA 6: 73193151 rs1334346 A C 0.83 −5.76 8E− 09
Contrast II (current
vs. mixed)
EA 5: 11232831 rs112030805 A G 0.92 −5.60 2E− 08
8: 27336978 rs2565059 G A 1.08 7.14 9E− 13
9: 136471660 rs112270518 G A 0.93 −5.64 2E− 08
11: 113344912 rs61902807 T C 1.06 6.34 2E− 10
19: 41339896 rs12459249 C T 0.94 −7.68 2E− 14
POP ancestral population, CHR chromosome, POS position, EA effect allele, NEA noneffect allele, OR odds ratio, Z Wald test statistics, PWald test p values, EA European American, AA African American,
HA Hispanic American.
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Fig. 2 Genome-wide association study results for smoking trajectory contrasts. Mirror Manhattan plots for smoking trajectory contrast I (current vs.
never (a)) and contrast II (current vs. mixed (b)) in European American samples in the Million Veteran Program. Genome-wide significant loci
are highlighted in red and mapped to genes by the nearest location. Genes have not been previously reported to be associated with smoking
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The third significant SNP—rs11697662 on chromosome 20—is a
novel locus for current CPD (β= 0.016; p= 6.93 × 10−9). For past
CPD, the most significant SNP, rs8040863, is a well-established
smoking-associated exonic variant on CHRNA3 (β= 0.044; Wald
test p= 1.80 × 10−20). Rs12459249, proximal to CYP2A6, pre-
viously associated with the nicotine metabolite ratio20, was also
GWS for past CPD (β=−0.033; Wald test p= 1.33 × 10−11). A
novel locus for past CPD was rs7571606 on TEX41 (β= 0.027;
Wald test p= 4.62 × 10−9). Thus, our GWAS of CPD both
replicated previously identified loci and yielded two novel loci for
a quantitative smoking trait.
We performed meta-analyses on a combined sample size of
842,717 individuals from the MVP and GSCAN cohorts
(excluding 23andMe) for two phenotypes separately: smoking
initiation and smoking cessation. We identified 99 independent
loci for smoking initiation and 13 loci for smoking cessation
(Supplementary Data 3). For smoking initiation, our meta-
analysis of MVP and GSCAN yielded 16 new loci, including
rs10446671 near to LOC101927285 and rs10211770 near to
LINC01441. For smoking cessation, two of 13 loci were not
reported in GSCAN: rs329120 near JADE2 and rs12891477 near
LINC00637.
Downstream analyses and biological interpretation of GWAS
results. As mentioned earlier, we applied downstream analyses to
the association results of the pairwise trajectory contrasts and
smoking status phenotypes obtained in EA samples in the MVP.
Here we studied SNP-based heritability and heritability enrich-
ments, gene prioritization and pathway enrichments for top sig-
nals identified in the GWASs, and summary statistics-based
genetic correlation and potential causal–consequential relation-
ships with other psychiatric and nonpsychiatric phenotypes.
Using LDSC35, the SNP heritability of smoking trajectory was
18.7% (SE= 0.010) for contrast I (current vs. never) and 5.8%
(SE= 0.005) for contrast II (current vs. mixed). The heritability of
smoking status in EAs was 6.9%, SE= 0.004 for smoking initiation
and 6.1%, SE= 0.005 for smoking cessation (Supplementary
Table 3). Thus, smoking trajectory I (current vs. never) accounted
for more SNP heritability than smoking initiation while smoking
trajectory II (current vs. mixed) has SNP heritability comparable to
smoking cessation.
To estimate tissue and cell type-specific heritability, we
conducted partitioned LD score regression using GenoSkyline-
Plus functional annotations only in EAs36,37. LDSC showed
significant heritability enrichments in multiple tissue and cell lines
(Supplementary Data 4). In contrast I (current vs. never), the most
significant heritability enrichment was for the anterior caudate in
brain (enrichment score= 5.4, Wald test p= 4.7 × 10−7). Other
significantly enriched cell types included the cingulate gyrus
(enrichment score= 5.8, p= 1.5 × 10−4), normal human astrocytes
(enrichment= 5.1, Wald test p= 1.1 × 10−04), and G-CSF-
mobilized hematopoietic CD34+ stem cells (enrichment= 3.7,
Wald test p= 9.0 × 10−5) (Supplementary Data 4). No significant
heritability enrichment was identified for contrast II (current vs.
mixed). The heritability of smoking status in the MVP-only sample
showed significant enrichment in the anterior caudate for smoking
initiation (enrichment= 5.7, Wald test p= 2.9 × 10−8) and in G-
CSF-mobilized hematopoietic CD34+ stem cells for smoking
cessation (enrichment= 5.3, Wald test p= 9.9 × 10−5) (Supple-
mentary Data 4).
To prioritize causal genes, we performed functional annotation
of the GWAS-identified genetic variants for smoking trajectory in
EA samples in the MVP by using co-localization analysis that
focused on two molecular traits, expression quantitative trait loci
(eQTLs) and histone interactions in brain tissues. We used the false
discovery rate (FDR) < 0.05 for the eQTL mapping and FDR < 1 ×
10−6 for the chromatin interaction mapping. Co-localization
analysis was separately performed for smoking trajectories,
contrast I (current vs. never) and contrast II (current vs. never)
using FUMA GWAS. For contrast I (current vs. never), we
identified 40 significant genomic regions co-localized among
18 significant loci and molecular traits (Supplementary Data 5).
Positional mapping identified 16 significant genes, eQTLs were
mapped to 28 genes in multiple brain regions including basal
ganglia and hippocampus, and chromatin interactions were
mapped to 21 genes in adult cortex. Importantly, co-localization
analysis showed that several well-known genes for smoking, e.g.,
DRD2, CHRNA2, TTC12, were causal genes (Fig. 3). For contrast II
(current vs. mixed), we identified five significant genomic regions.
Positional mapping revealed three significant genes (TTC12,
CHRNA2, and CYP2A7); eQTL mapping identified an additional
significant gene, EPHX2, in the brain cerebellar hemisphere; and
chromatin interaction mapping identified two significant genes,
TTC12 and TMPRSS5 in adult cortex (Supplementary Data 5)
(Fig. 3). The mapped brain cortex, hippocampus, and basal ganglia
regions are functionally involved in reward reinforcement,
cognitive processing, and emotion regulation and thus have
implications for the etiology of addictive behaviors and their
association with other neuropsychiatric disorders including
depression38–40. These findings provide further support that
GWAS for smoking trajectory identified biologically meaningful
signals.
Using the Database for Annotation, Visualization and
Integrated Discovery (DAVID)41 to conduct pathway analysis
for smoking trajectories, we identified 23 significant pathways for
smoking trajectory contrast I (current vs. never) and 4 for
trajectory contrast II (current vs. mixed) (Supplementary Data 6).
The top enriched pathways for trajectory contrast I (current vs.
never) were identified for the histone H1 gene cluster and were
involved in DNA packaging complex, nucleosome assembly and
organization, and chromatin assembly/disassembly activities. The
top enriched pathways for trajectory contrast II (current vs.
mixed) were identified for the CYP2 gene cluster and were related
to epoxygenase, oxidoreductase, and monooxygenase activities.
We used GeNetic cOVariance Analyzer (GNOVA) to estimate
genetic correlations between smoking trajectory contrasts in EA
samples from the MVP and 524 psychiatric and nonpsychiatric
traits for which large-scale summary statistics are available42,43. We
found 209 significant genetic correlations (Bonferroni-corrected
p < 0.05/524/2= 4.8 × 10−5) between at least one of the trajectory
contrasts and other traits (Supplementary Data 7). As shown in
Fig. 4, smoking trajectory contrasts were significantly genetically
correlated with other smoking-related phenotypes, alcohol pheno-
types, and psychiatric disorders, including positive correlations
with depressive symptoms and schizophrenia. There were also
significant positive genetic correlations between smoking trajectory
contrasts and lung disease, coronary artery disease, diabetes,
obesity, and negative correlations between smoking and overall
health rating. All of these findings are expected and consistent with
previous reports.
To understand causal–consequential relationships between
smoking trajectory and significantly genetically correlated traits,
we performed a bi-directional two-sample MR analysis for
smoking trajectory contrast I (current vs. never) and contrast II
(current vs. mixed) separately. Here, significant SNPs from the
trajectory GWAS served as an instrumental variable, smoking
trajectory as an exposure, and a psychiatric or nonpsychiatric trait
as an outcome variable; MR analyses were also performed with
smoking trajectory as an outcome and the various complex traits
as exposures. Trait pairs with three or fewer instrumental
variables were excluded from the analysis. We used four MR
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methods: inverse-variance weighted (IVW), weighted median
(WM), MR-Egger regression (MR-Egger), and MR-PRESSO to
test the causal relationships. We applied a Bonferroni correction
to correct for different MR methods and all combinations of
causal paths. We present causal paths for statistically significant
traits identified by one of the four MR methods.
We identified five significant causal paths using trajectory
contrast I (current vs. never) as an exposure and 23 significant
causal paths using it as an outcome. While no significant results
identified using trajectory contrast II (current vs. mixed) as an
exposure, 12 were identified as being significant using it as an
outcome (Supplementary Data 8). MR-Egger seemed to be the
most conservative and identified no significant causal relation-
ship or pleiotropic effect. While the significance varied across
methods, the magnitude and direction of estimated causal
effects were highly consistent across IVW, median weighted,
and MR-PRESSO. Our analyses suggested multiple interesting
causal–consequential relationships. For example, in trajectory
contrast I (current vs. never), smoking was a cause of wheeze or
whistling in the chest in last year, while depression (fed-up
feelings) likely led to smoking. Smoking was an outcome of
multiple traits related to body weight including body mass index
and whole-body fat mass. Interestingly, we found that higher
education likely had a causal effect on smoking behavior. We
found no trait pair with both significant forward and reverse
causal relationships. It is noted that the statistical significance is
inadequate to claim a causal relationship between trait pairs.
The identified significant MR results serve as suggestive
evidence for further investigation and the causal relationships
should be interpreted with caution.
Discussion
We present data from a GWAS of smoking phenotypes in the
MVP, the largest relatively homogeneous clinical sample studied
to date, and combine these results with a published study to
yield a large meta-analysis for smoking status. We identified
more than a dozen significant genetic risk loci for smoking
trajectories in the MVP. A meta-GWAS of MVP and GSCAN in
European-ancestry individuals identified more than 100 loci for
smoking status, including loci that were not seen in either MVP
or GSCAN alone. The loci identified in the MVP cohort account
for more genetic heritability in smoking behavior than previous
studies5,10. The heritability was enriched in brain regions rela-
ted to smoking behavior. We prioritized 40 genes strongly
associated with biological functions relevant to smoking tra-
jectory of current vs. never, including neural and synaptic
function. Smoking-associated loci were highly correlated with
209 smoking-related psychiatric and nonpsychiatric pheno-
types. We found 33 significant causal relationships between
MVP EA trajectory: Current vs. Never 
MVP EA trajectory: Current vs. Mixed 
Chromosome 8 
Chromosome 8 
Chromosome 11 
Chromosome 11 
rs2565060
rs
31
33
38
8
rs2565059
rs61902807
a
b
Fig. 3 Gene prioritization for smoking trajectory contrasts. Functional mapping and annotation (FUMA) gene prioritization for smoking trajectory
contrast I (current vs. never (a)) and contrast II (current vs. mixed (b)) in European American samples in the Million Veteran Program. The outer layer
shows chromosomal Manhattan plots. Region in blue shows genome-wide significant locus. Genes mapped by chromatin interactions and eQTLs are
colored in orange and green, respectively. Genes mapped by both chromatin interactions and eQTLs are colored in red.
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smoking trajectory and other smoking phenotypes, alcohol
consumption, and psychiatric traits. Together, our results pro-
vide new insights into genetic risks for smoking behavior and
implicate loci to be validated biologically in future studies.
We leveraged robust EMR data to yield a longitudinal phe-
notype for the trait of smoking trajectories. This novel phenotype
identified genomic loci for smoking trajectories overlapping with
those from a meta-analysis of smoking status in a much larger
sample5,10. Thus, longitudinal smoking trajectories may offer
greater power to detect novel genetic variants than the widely
used binary phenotype of ever vs. never smoked. We identified
several interesting loci for smoking trajectory. A locus containing
neuronal growth regulator 1 (NEGR1) was associated with the
smoking trajectory of current vs. never. NEGR1 encodes a protein
involved in neuronal development and maturation44,45; the gene
has been associated with major depression46 and showed altered
gene expression in the prefrontal cortex of schizophrenic
patients47. A variant in NEGR1 was also previously linked to
obesity48, which, like smoking, involves a dysregulation of
appetitive behavior. Several loci associated to smoking trajectory
were also associated with other relevant phenotypes. A locus
containing CNNM2, which was significantly associated with
smoking trajectories in this study, was recently linked to smoking
behavior in a large meta-analysis6. A variant in CAMKMT for
smoking trajectories in the MVP was previously associated with
anxiety disorder49.
Some of the genes identified in the meta-analysis for smoking
status are particularly noteworthy. For example, rs6265 on BDNF
(Wald test p= 1.3 × 10−14) is a well-established exonic func-
tional SNP for psychiatric disorders50,51, including smoking
behavior. One of the loci located in NRXN1 (Neurexin 1, index
SNP rs11125335, Wald test p= 1.1 × 10−11) was previously
associated to nicotine dependence52. Neurexins are cell-surface
receptors that bind neuroligins to form Ca(2+)-dependent
neurexin/neuroligin complexes at synapses in the central nervous
system53. This locus was previously identified as a candidate gene
but was not GWS in the TAG samples12. Genetic variation in
NRXN1 has also been linked to autism spectrum disorder54,
attention deficit hyperactivity disorder55, and schizophrenia56.
One of the significant signals for smoking status was from
NCAM1, index SNP rs7110863 (Wald test p= 1.6 × 10−35),
which was highly significant for smoking trajectory in the MVP
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Fig. 4 Genetic correlations between smoking trajectory contrasts and multiple complex traits. Complex traits with significant genetic correlations with
smoking trajectory contrast I (current vs. never (a)) and contrast II (current vs. mixed (b)) in European American samples in the Million Veteran Program.
Asterisk indicates significance after Bonferroni correction with a Wald test p value cutoff at 0.05/524/2= 4.8 × 10−5. Detailed information on the exact
p values, data source, and sample sizes for each complex trait is summarized in the Supplementary Data 7.
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(index SNP rs7126748; Wald test p= 4.2 × 10−8). NCAM1 is
located in a well-known genomic region on chromosome 11,
NCAM1-TTC12-ANKK1-DRD2, previously associated with
nicotine dependence28 and smoking motives57.
Of note, despite several recently reported large GWASs for
smoking traits5,10 that revealed more loci than the present study,
the estimated heritability of smoking for trajectory contrast I
(current vs. never) in our study is substantially higher than that in
previous studies (>15% for contrast I vs. <10% for other smoking
traits). These results suggest that smoking trajectories are a more
powerful trait for detecting genome-wide signals with small effects
on smoking behavior. A higher SNP heritability level in our sample
also suggests that meta-GWAS from the multiple cohorts may be
missing vulnerability for smoking traits, possibly due to hetero-
geneity in the meta-GWAS. Note that our results estimated with
LDSC were based on a heritability model that assumes that all
genetic variations contribute equally to the SNP-based heritability
and the summary statistics were derived after adjusting for age, sex,
and top ten PCs as covariates. The heritability estimation is subject
to inadequate covariate adjustment and novel methods developed to
provide a more flexible specification of heritability model are worth
future investigation58–60.
We were unable to replicate the identified loci associated with
smoking trajectories in an independent sample due to a lack of a
replication cohort with comparable longitudinal measurements of
smoking behavior. We identified only one locus for smoking
trajectory in the AA and HA populations, likely due to the
modest sample sizes in these populations. The findings from
trans-ancestry meta-analysis mostly reflect the findings from the
EA samples. In addition, the majority of our samples were men,
so that it was not feasible to examine sex-specific genetic risks.
In conclusion, compared to more widely used, simple smoking
phenotypes, we demonstrated that (1) longitudinal EMR data
permit the estimation of smoking trajectories, and (2) these
phenotypes yield greater statistical power to detect small-effect
variants, enabling the detection of novel genetic risk variants for
smoking behavior.
Methods
Study cohort. The MVP recruited veteran volunteers and collects data from ques-
tionnaires, EMRs, and blood samples for genomic analysis. The Central Veterans
Affairs Institutional Review Board (IRB) and site-specific IRBs approved the MVP
study. All relevant ethical regulations for work with human subjects were followed in
the conduct of the study and informed consent was obtained from all participants.
We selected 26,497 LD pruned SNPs and applied flashpca version 1.2.5 to
perform PC analysis on 343,268 unrelated MVP samples and 2504 1000 Genomes
Project (1KG) samples to identify population structure. The annotated Euclidean
center of European, African, admixed American, East Asian, and South Asian 1KG
samples plus the admixture analysis results with a probability cutoff of 0.8 were
used to define populations. We removed samples with a high genotype missing rate
(>10%), discordant sex, excessive heterozygosity (>3 sd), and up to second-degree
relatives. A total of 209,915 EAs, 54,867 AAs, and 21,336 HAs passed quality
control filters. The mean age of the study cohort ranged from 58 to 64 years across
three ancestral groups (EA: mean= 64, standard deviation (SD)= 13, AA:
mean= 58, SD= 12, and HA: mean= 56, SD= 15) and majority of the MVP
samples were male (EA: 93%, AA: 87%, and HA: 92%).
Smoking phenotypes. Smoking data from 2000 to 2015 were obtained from the
Veteran Healthcare Administration Corporate Data Warehouse. Details on the
data extraction methods are provided elsewhere61. In brief, EMR smoking data are
collected nationally from patients approximately annually using the clinical
reminder process, which prompts providers to ask patients questions related to
health. EMR smoking data consist of text values that represent responses to the
specific smoking-related queries to patients, which can vary by site and over time.
Mapping strategies were created to classify these responses into never, past, and
current smoking status and can be found on www.vacohort.org61.
Smoking trajectory phenotype accounts for variation in smoking status over
time22. We used joint trajectory modeling to sort each participant’s smoking values
(current, past, never) into clusters and estimated distinct trajectories62–64. We used
age as the time scale to account for possible decreases in smoking with age. The
procedure calculated each individual’s probability of belonging to each trajectory
and assigned the individual to the trajectory with the highest probability of
membership (mostly current smoking, mixed smoking and nonsmoking, mostly
never smoking). Applying the phenotype definition, we identified 40,456 mostly
current smokers, 110,403 mixed smokers, and 59,056 mostly never smokers in EAs,
13,511 mostly current smokers, 23,605 mixed smokers, and 17,751 mostly never
smokers in AAs, and 2920 mostly current smokers, 11,221 mixed smokers, and
7195 mostly never smokers in HAs.
Using all available EMR smoking observations, we used the most common
(modal) value for smoking status assessment. We identified 72,729 never smokers,
71,002 past smokers, and 66,184 current smokers in the EA sample. We further
contrasted ever smoked (past or current smokers) with never smoked
(nonsmokers) to study smoking initiation behavior. Similarly, we used the modal
value of smoking status classification and contrasted current with past to reflect
smoking cessation phenotype.
Cigarettes per day was based on responses to the MVP baseline survey
questionnaire. The subjects were asked, “Do you currently smoke cigarettes?”,
If yes, then “How many cigarettes do you smoke per day now?”. If no, then “Over
the entire time you smoked, on average, how many cigarettes did you smoke
per day?”. The responses were on a scale from 1 to 5, corresponding to (1) less than
a half pack, (2) a half pack, (3) 1 pack, (4) 2 packs, and (5) more than 2 packs. We
identified 17,014 and 77,515 individuals for CPD current and CPD past with
nonmissing responses, respectively.
Genotyping, imputation, and quality control. MVP used an Affymetrix Axiom
Biobank Array that genotyped ~723,000 markers, which were enriched for exonic
variants. SNPs were validated for common diseases and phenotypes of specific
interest to the VA population (e.g., psychiatric traits)65. Minimac3 and the 1000
Genomes Project 3 reference panel were used to conduct genotype imputation,
which resulted in ~79 million variants in this study66. We filtered out rare variants
(minor allele frequency < 0.01), variants with a missing rate > 5%, variants with
imputation r2 < 0.8, and those that deviated significantly from Hardy–Weinberg
equilibrium (p < 1 × 10−6).
Single nucleotide polymorphism (SNP) association analysis. For the trajectory
GWAS, we applied a multinomial regression analysis using SNPTEST (v2.5.4-beta2)
to test for an association of SNPs with trajectories. The overall fit of the model was
evaluated using the likelihood ratio test, which assessed the strength of the relation-
ship between each genetic variation and the multinomial smoking trajectory groups
by comparing the fit of two models with and without the genetic variation. The two
trajectory contrasts were modeled simultaneously, which resulted in smaller standard
error estimates of genetic effects and thus greater statistical power. We estimated
genetic effects for two trajectory contrasts: contrast I (current vs. never) and contrast
II (current vs. mixed). For the smoking status phenotype modal value that defined
smoking initiation and smoking cessation, we applied logistic regression to estimate
marginal effects of each single genetic variant on smoking. For the CPD phenotype,
we used linear regression analysis. We used PLINK (v1.9) to performed logistic and
linear regression association analyses. In each model, we included age and sex as
covariates and the ten top PCs calculated with flashpca (v1.2.5) to adjust for popu-
lation stratification. Quantile–quantile plots were generate to evaluate the extent to
which the observed GWAS p values deviated from the null hypothesis (Supplemen-
tary Fig. 5). The LD score regression intercept was used to quantify inflation resulting
from confounding bias35. We identified proxy independent SNPs (LD, r2 < 0.1) and
selected the ones with the most significant p values as index SNPs. We then defined a
risk locus as a physical region containing all GWS variants (p < 5 × 10−8) that were in
LD (r2 > 0.6) with the index SNP. Loci within 250 kilobases were merged67,68. We
used ANNOVAR (v2016Feb01) to annotate index SNPs with their nearest genes69.
Loci mapped to the same nearest gene were merged to yield one risk locus. We
summarized whether the identified locus in the MVP was mapped to a gene pre-
viously reported to be associated with smoking phenotypes in other studies. If it was,
we also listed the associated smoking phenotypes. The results are based on a literature
review and query search in the GWAS Catalog70. LocusZoom (v1.3) was used to
visualize regional associations and LD patterns71.
Meta-analysis of GWAS results. We meta-analyzed GWAS summary statistics of
smoking status phenotypes (smoking initiation meta N= 842,717, smoking ces-
sation meta N= 450,129) in the MVP EA samples (N= 209,915), and GSCAN
excluding 23andMe samples (N= 632,802). The summary statistics from 23andMe
are not publicly available. We also performed trans-ethnic meta-analyses of the
trajectory phenotypes (contrast I meta N= 140,889, contrast II meta N= 202,116)
in EAs, AAs, and HAs in the MVP. Meta-analyses were performed using inverse-
variance mixed effects model implemented in METAL (v2011-03-25) with the test
statistics and standard errors scheme72. We enabled the genomic control correction
option on all GWAS results in the meta-analysis.
Downstream analysis for smoking GWASs in European Americans. Herit-
ability estimation and enrichment analyses were performed for smoking initiation,
smoking cessation, smoking trajectory contrast I (current vs. never), and smoking
trajectory contrast II (current vs. mixed) in the MVP EA samples. We applied LD
score regression (v1.0.0) to estimate the narrow-sense heritability due to additive
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genetic effects35. We also estimated heritability enrichments to identify tissue and
cell types that were the most relevant to smoking-related traits36. We used 66
functional annotations from GenoSkyline-Plus (v1.0.0) including tissues and cell
lines from blood, brain, lung, vascular, heart, thymus, spleen, muscle, gastro-
intestinal, pancreas, liver, fat, bone/connective, skin, breast, and ovary for the
heritability enrichment analysis37. Bonferroni correction was applied to the 66
enrichment tests for two smoking trajectory contrasts and two smoking status
phenotypes, resulting in a significance cutoff of 0.05/66/4= 1.9 × 10−4.
We performed functional gene mapping for two smoking trajectory contrasts in
the MVP EA samples. Positional, eQTL, and chromatin interaction mapping was
performed using the functional mapping and annotation tool FUMA (v1.3.6)73. We
used the default parameter settings for the identification of lead and candidate SNPs
except for changing the maximum distance to 250 kilobases to merge LD blocks into a
locus. The change was consistent with the distance parameter we used in previous
genetic loci definition. Positional mapping was performed with the default parameter
setting. eQTL mapping was restricted to 13 GTEx v8 brain tissues. We used the built-
in adult cortex Hi–C data and enhancer/promoter annotations in 12 brain tissues
from Roadmap epigenomes to perform chromatin interaction mapping. By default,
we used FDR < 0.05 for the eQTL mapping and FDR < 1 × 10−6 for the chromatin
interaction mapping. The functional annotation and gene mapping parameter setting
and results are available on the FUMA public results section.
We used DAVID (v6.8) to perform pathway-enrichment analysis on GWAS
variants with p values less than 1 × 10−5 41. ANNOVAR was used to map variants
to their nearest genes69. Smoking trajectory contrast I (current vs. never) had 344
genes mapped from 6296 variants and smoking trajectory contrast II (current vs.
mixed) had 130 genes mapped from 877 variants. Gene Ontology (GO) terms in
three categories (GO: biological process, GO: cellular component, and GO:
molecular function) were used for pathway-enrichment analyses and biological
interpretation69. From 550 pathway-enrichment tests, 321 and 229 GO terms
contained genes that overlapped with smoking trajectory contrast I (current vs.
never) and smoking trajectory contrast II (current vs. mixed), respectively.
Bonferroni correction was applied to correct for 550 tests, yielding a significance
cutoff of 0.05/550= 9.1 × 10−5.
We used GNOVA to estimate genetic correlations between smoking trajectory
phenotypes and other traits and diseases with publicly available summary
statistics42. GWAS summary statistics for 524 complex traits and diseases were
downloaded from LD Hub and recent publications on addictive behaviors43. For
the UKBB phenotypes integrated in LD Hub, we manually filtered out lifestyle and
environmental traits with a keyword search for sport, activity, exercise, driving,
transportation, travel, job, and employment. Bonferroni correction was applied to
the 524 correlations and two smoking trajectory contrasts, yielding a significance
cutoff of 0.05/524/2= 4.8 × 10−5.
Bi-directional Mendelian randomization (MR) was performed on trait pairs
identified with significant genetic correlations. Instrumental variables were selected
as GWS SNPs for the exposure excluding those GWS for the outcome to satisfy the
MR assumptions. Trait pairs with 3 or fewer instrumental variables were excluded
from the analysis, leaving 638 trait pairs to be tested for causal relationships. We
used four MR methods: IVW, WM, MR-Egger, and MR-PRESSO implemented in
the MendelianRandomization (v0.4.2) and MR-PRESSO (v1.0) R packages74–77. We
tested the intercept term from the MR-Egger to detect potential horizontal
pleiotropic effects. We also used MR-PRESSO to identify outliers of instrumental
variables with pleiotropic effects. The significance cutoff for outlier identification
was calculated as 0.05/number of instrumental variables. If outliers were identified,
we reported causal estimates obtained by MR-PRESSO after removing the outliers.
In the absence of outliers, the MR-PRESSO provided results identical to those from
IVW. We used t-test statistics to derive p values from all four methods for
comparability. We applied a Bonferroni correction on bi-directional MR tests on
trait pairs with more than three instrumental variables and each was tested with four
methods, resulting in a significance cutoff of 0.05/638/4= 1.96 × 10−5.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The full summary-level association data from the meta-analysis for each of the smoking-
related traits from this report are available through dbGaP accession number phs001672.
v4.p1. 1000 Genomes Project reference panel can be downloaded from [ftp://
ftp.1000genomes.ebi.ac.uk/vol1/ftp/]. GWAS summary statistics used in the genetic
correlation analysis were made publicly available by GSCAN, Social Science Genetic
Association Consortium (SSGAC) [https://www.thessgac.org/data], and LD Hub.
Code availability
Code to perform analyses in this paper is available from the authors upon request (B.L.),
or from the URLs associated with each software in the online methods section.
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